SG11201805263TA - Compositions and methods for detecting and treating esophageal cancer - Google Patents
Compositions and methods for detecting and treating esophageal cancerInfo
- Publication number
- SG11201805263TA SG11201805263TA SG11201805263TA SG11201805263TA SG11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- esophageal cancer
- compositions
- rule
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G01N33/57557—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G01N33/57585—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307189 | 2015-12-31 | ||
| EP16305139 | 2016-02-05 | ||
| PCT/EP2017/050037 WO2017114976A1 (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating esophageal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805263TA true SG11201805263TA (en) | 2018-07-30 |
Family
ID=57821946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805263TA SG11201805263TA (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating esophageal cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11789021B2 (enExample) |
| EP (2) | EP3848709B1 (enExample) |
| JP (2) | JP7018885B2 (enExample) |
| KR (2) | KR102197478B1 (enExample) |
| CN (1) | CN108700589A (enExample) |
| AU (2) | AU2017204686B2 (enExample) |
| BR (1) | BR112018013272A2 (enExample) |
| CA (2) | CA3193481A1 (enExample) |
| EA (1) | EA037032B1 (enExample) |
| ES (2) | ES3003287T3 (enExample) |
| PL (1) | PL3397967T3 (enExample) |
| SG (1) | SG11201805263TA (enExample) |
| WO (1) | WO2017114976A1 (enExample) |
| ZA (1) | ZA201804142B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240018264A1 (en) * | 2015-12-31 | 2024-01-18 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating ovarian cancer |
| EP3720879B1 (en) * | 2017-12-05 | 2022-05-11 | Progastrine et Cancers S.à r.l. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
| AU2018381046B2 (en) | 2017-12-08 | 2025-10-02 | Ecs-Biotracker Sàrl | Radiolabeled progastrin in cancer diagnosis |
| TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ｅｃｓ前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
| WO2019166499A1 (en) | 2018-02-27 | 2019-09-06 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
| CA3093053A1 (en) * | 2018-03-13 | 2019-09-19 | Creatv Microtech, Inc. | Methods for monitoring treatment response and disease progression in subjects using circulating cells |
| KR102167078B1 (ko) * | 2019-07-19 | 2020-10-16 | (주)파즈코리아 | 혈액 샘플 이송 장치 |
| US20220356532A1 (en) * | 2019-10-24 | 2022-11-10 | The Johns Hopkins University | Compositions and methods for detecting and treating esophageal cancer |
| JP7287532B2 (ja) * | 2020-08-04 | 2023-06-06 | 王子ホールディングス株式会社 | トイレットロール |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CN1525868A (zh) * | 2001-07-09 | 2004-09-01 | 埃弗顿有限公司 | 治疗和预防肝脏、肺脏和食道的癌症和癌症前期症状 |
| JP2008513536A (ja) * | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | プロガストリンに対するモノクローナル抗体 |
| EP2010569A4 (en) * | 2006-03-20 | 2009-09-09 | Xoma Technology Ltd | HUMAN ANTIBODIES SPECIFIC TO GASTRINE MATERIALS AND METHODS |
| US7854932B2 (en) * | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| US20110085986A1 (en) | 2009-10-13 | 2011-04-14 | Pomila Singh | Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides |
| US8900588B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
| SG184092A1 (en) * | 2010-03-24 | 2012-10-30 | Biorealites | Prophylaxis of colorectal and gastrointestinal cancer |
| ES2871092T3 (es) | 2010-07-26 | 2021-10-28 | Progastrine Et Cancers S A R L | Métodos y composiciones para la terapia del cáncer de hígado |
| FI20145550A7 (fi) | 2014-06-13 | 2015-12-14 | Biohit Oyj | Gastriini-17 käyttö biomarkkerina atrofiselle gastriitille ja usealle sen seurauksena kohonneelle riskille |
| WO2016066671A1 (en) * | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
-
2017
- 2017-01-02 CA CA3193481A patent/CA3193481A1/en active Pending
- 2017-01-02 KR KR1020187020013A patent/KR102197478B1/ko active Active
- 2017-01-02 EA EA201891527A patent/EA037032B1/ru unknown
- 2017-01-02 AU AU2017204686A patent/AU2017204686B2/en active Active
- 2017-01-02 SG SG11201805263TA patent/SG11201805263TA/en unknown
- 2017-01-02 PL PL17700483T patent/PL3397967T3/pl unknown
- 2017-01-02 ES ES20217589T patent/ES3003287T3/es active Active
- 2017-01-02 BR BR112018013272-1A patent/BR112018013272A2/en not_active IP Right Cessation
- 2017-01-02 WO PCT/EP2017/050037 patent/WO2017114976A1/en not_active Ceased
- 2017-01-02 ES ES17700483T patent/ES2861587T3/es active Active
- 2017-01-02 KR KR1020207037405A patent/KR102430893B1/ko active Active
- 2017-01-02 EP EP20217589.9A patent/EP3848709B1/en active Active
- 2017-01-02 CA CA3009785A patent/CA3009785A1/en active Pending
- 2017-01-02 JP JP2018534930A patent/JP7018885B2/ja active Active
- 2017-01-02 CN CN201780013902.0A patent/CN108700589A/zh active Pending
- 2017-01-02 EP EP17700483.5A patent/EP3397967B1/en active Active
- 2017-01-02 US US16/067,208 patent/US11789021B2/en active Active
-
2018
- 2018-06-20 ZA ZA201804142A patent/ZA201804142B/en unknown
-
2020
- 2020-03-31 AU AU2020202296A patent/AU2020202296B2/en active Active
-
2022
- 2022-01-31 JP JP2022013712A patent/JP7363007B2/ja active Active
-
2023
- 2023-09-15 US US18/468,096 patent/US20240085423A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201891527A1 (ru) | 2019-01-31 |
| ES2861587T3 (es) | 2021-10-06 |
| EP3848709A1 (en) | 2021-07-14 |
| KR102430893B1 (ko) | 2022-08-09 |
| EP3397967B1 (en) | 2020-12-30 |
| CA3193481A1 (en) | 2017-07-06 |
| JP2022064969A (ja) | 2022-04-26 |
| AU2017204686A1 (en) | 2018-07-05 |
| AU2020202296B2 (en) | 2022-06-02 |
| CN108700589A (zh) | 2018-10-23 |
| PL3397967T3 (pl) | 2021-06-28 |
| US20240085423A1 (en) | 2024-03-14 |
| CA3009785A1 (en) | 2017-07-06 |
| EP3848709B1 (en) | 2024-12-04 |
| US11789021B2 (en) | 2023-10-17 |
| EP3848709C0 (en) | 2024-12-04 |
| KR102197478B1 (ko) | 2021-01-04 |
| JP7363007B2 (ja) | 2023-10-18 |
| KR20180108586A (ko) | 2018-10-04 |
| AU2020202296A1 (en) | 2020-04-23 |
| JP2019505785A (ja) | 2019-02-28 |
| EA037032B1 (ru) | 2021-01-28 |
| JP7018885B2 (ja) | 2022-02-14 |
| BR112018013272A2 (en) | 2018-12-11 |
| US20190011447A1 (en) | 2019-01-10 |
| AU2017204686B2 (en) | 2020-04-30 |
| EP3397967A1 (en) | 2018-11-07 |
| WO2017114976A1 (en) | 2017-07-06 |
| ZA201804142B (en) | 2019-11-27 |
| ES3003287T3 (en) | 2025-03-10 |
| KR20210002363A (ko) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805263TA (en) | Compositions and methods for detecting and treating esophageal cancer | |
| SG11201805605TA (en) | Compositions and methods for detecting and treating ovarian cancer | |
| SG11201908888VA (en) | Compositions and methods for treating lung cancer | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201908998XA (en) | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201407802WA (en) | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201408605UA (en) | Methods for biodegradable derivatization of cellulosic surfaces | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11201907693VA (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau |